FPFernando Puyol-Ruiz

Fernando Puyol-Ruiz

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Fernando Puyol-Ruiz has a total of 23 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Intra-Individual Variability of Lipoprotein(a) After Acute Coronary Syndrome: A Long-Term Cohort Study

    by Nelsa González-Aguado, Jose Ignacio Larrubia-Valle, Rafael Franco-Hita, Alberto Piserra-López, Arancha Díaz-Expósito, Victoria García-Ruiz, Fernando Puyol-Ruiz, Óscar Barquero-Alegre, Fernando Carrasco Chinchilla, Antonio Domínguez-Franco, et al.

    Background: Lipoprotein(a) [Lp(a)] is a causal and independent risk factor for atherosclerotic cardiovascular disease (ASCVD) and is largely genetically determined. However, recent studies indicate significant intra-individual variability, particularly among patients with intermediate Lp(a) levels (30–50 mg/dL). Yet, data on long-term variability are limited, and acute coronary syndrome (ACS) may further influence Lp(a) levels, raising questions regarding the optimal timing of assessment after ACS. Methods: We studied 235 ACS patients across two follow-up cohorts. Baseline Lp(a) was measured 24 h before hospital discharge. Cohort A had follow-up measurements at 4 months and 8 months; Cohort B had them at 5 years. Clinically meaningful intra-individual variability was defined as ≥20 mg/dL or ≥25% change. Results: 57.9% of patients exhibited clinically significant Lp(a) variability. Changes in risk category occurred in 15.3% of patients in the baseline high-risk group, 60.6% of patients in the intermediate-risk group, and 5.5% of patients in the baseline low-risk group. In the multivariable analysis, incomplete revascularization was an independent predictor of high Lp(a) variability (odds ratio (OR) 2.22; 95% confidence interval (CI) 1.14–4.31; p = 0.02) while female sex and age-adjusted menopause showed a trend (OR 1.92; 95% CI 0.93–4.00; p = 0.08 and OR 11.18; 95% CI 0.79–157.58; p = 0.07, respectively) without reaching statistical significance. The median absolute changes from baseline to 4-month and from baseline to 5-year follow-up were 7.9 mg/dL (interquartile range (IQR) 3.0–18.9) and 10.7 mg/dL (IQR 3.0–21.7), respectively. Concordance between 4- and 8-month Lp(a) measurements was excellent. Conclusions: Early post-ACS intra-individual variability in Lp(a) is common, mainly affecting risk reclassification in intermediate-risk patients. In those patients, early, targeted, repeat Lp(a) measurement may improve cardiovascular risk stratification, whereas mid- to long-term reassessment appears unnecessary.


  • Open Access

    Intra-Individual Variability of Lipoprotein(a) After Acute Coronary Syndrome: A Long-Term Cohort Study

    by Nelsa González-Aguado, Jose Ignacio Larrubia-Valle, Rafael Franco-Hita, Alberto Piserra-López, Arancha Díaz-Expósito, Victoria García-Ruiz, Fernando Puyol-Ruiz, Óscar Barquero-Alegre, Fernando Carrasco Cinchilla, Antonio Domínguez-Franco, et al.

    Background: Lipoprotein(a) [Lp(a)] is a casual and independent risk factor for atherosclerotic cardiovascular disease (ASCVD) and is largely genetically determined. However, recent studies indicate significant intra-individual variability, particularly among patients with intermediate Lp(a) levels (30–50 mg/dL). Yet, data on long-term variability are limited, and acute coronary syndrome (ACS) may further influence Lp(a) levels, questioning the optimal timing of assessment after ACS. Methods: We studied 235 ACS patients across two follow-up cohorts. Baseline Lp(a) was measured 24 hours before hospital discharge. Cohort A had follow-up measurements at 4 months, and 8 months; Cohort B at 5 years. Clinically meaningful intra-individual variability was defined as ≥20 mg/dL or ≥25% change. Results: A total of 57.9% patients exhibited clinically significant Lp(a) variability. Changes in risk category occurred in 15.3% of patients in the baseline high-risk group, 60.6% of patients in the intermediate-risk group, and 5.5% of patients in the baseline low-risk group. At multivariable analysis incomplete revascularization was an independent predictor of high Lp(a) variability (OR 2.22; 95% CI 1.14-4.31; p 0.02) while female sex, and age-adjusted menopause showed a trend (OR 1.92; 95% CI 0.93-4.00; p 0.08 and OR 11.18; 95% CI 0.79-157.58; p 0.07, respectively) without reaching formal statistical significance. The median absolute changes from baseline to 4-month and from baseline to 5-years follow-up were 7.9 mg/dL (IQR 3.0-18.9) and 10.7 mg/dL (IQR 3.0-21.7), respectively. Concordance between 4- and 8-month Lp(a) measurements was excellent. Conclusions: Early post-ACS intra-individual variability in Lp(a) is common, mainly affecting risk reclassification in intermediate-risk patients. In those patients, early targeted repeat Lp(a) measurement may improve cardiovascular risk stratification, whereas mid- to long-term reassessment appears unnecessary.


  • Open Access

    Impact of Lipoprotein (a) on Residual Cardiovascular Risk after an Acute Coronary Syndrome

    by Nelsa González -Aguado, Rafael Franco-Hita, Jose Ignacio Larrubia-Valle, Fernando Puyol-Ruiz, Ainhoa Robles-Mezcua, Jose Manuel García-Pinilla, María Jiménez-Salva, Alberto Piserra-López, Francisco Javier Pavon-Moron, Alejandro Pérez-Cabeza, et al.

    Reducing residual cardiovascular risk following an acute coronary syndrome (ACS) remains a major unmet clinical need. Despite substantial advances in lipid-lowering therapies, the risk of recurrent major adverse cardiovascular events (MACE) after ACS remains high, with an estimated incidence of approximately 33.4% at 5 years. Residual cardiovascular risk is driven by multiple mechanisms, including persistent inflammation, a prothrombotic status, metabolic disturbances, and the presence of atherogenic lipoproteins beyond low-density lipoprotein cholesterol (LDL-C). Lipoprotein(a) [Lp(a)] is a pro-inflammatory, pro-thrombotic and pro-atherosclerotic lipoprotein which seems to play a major role in the residual risk post ACS or atherosclerotic ischemic stroke. Elevated Lp(a) is a well-established independent and causal risk factor for atherosclerotic cardiovascular disease (ASCVD). Nevertheless, evidence regarding its prognostic value specifically after ACS remains limited, with marked heterogeneity across studies, which complicates direct comparisons and interpretation. In addition, while Lp(a) levels are predominantly genetically determined, recent studies have reported intra-individual variability, although its clinical significance remains uncertain. Finally, current therapeutic options specifically targeting Lp(a) are limited. Novel RNA-based therapies, including antisense oligonucleotides, small interfering RNAs, and emerging gene-editing approaches, have demonstrated profound and sustained reductions in circulating Lp(a) levels. Yet, whether this biological effect translates into reductions of hard clinical endpoints is under evaluation in ongoing clinical trials. This review aims to synthesize current evidence on the role Lp(a) as a major contributor to residual cardiovascular risk following ACS.